Bio-Techne To Host Conference Call On May 2, 2018 To Announce Third Quarter 2018 Financial Results

MINNEAPOLIS, April 11, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on May 2, 2018, at 8:00 a.m. CDT to review third quarter 2018 financial results.


Access to the discussion may be obtained as follows:

Time: 8:00 a.m. CDT
Date: May 2, 2018
Dial-in: 1-866-548-4713 or 1-323-794-2093 (for international callers)
Conference ID: 9276690

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call.  To access the recording, U.S. callers should dial 1-844-512-2921 or international callers should dial 1-412-317-6671 and enter the replay access code 9276690. The recording can also be accessed by going to:

The replay will be available from 11:00 a.m. CDT on Wednesday, May 2, 2018 until 11:00 p.m. CDT on Saturday, June 2, 2018.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds and ACD's in-situ hybridization detection products --- which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotech Division, headquartered in Minneapolis, Minnesota.  The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM customer and clinical customers. Bio-Techne products are integral components of scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $563 million in net sales in fiscal 2017 and has approximately 1,800 employees worldwide. For more information on Bio-Techne and its brands, please visit


David Clair, Investor



Cision View original content with multimedia:

SOURCE Bio-Techne Corporation